Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 268

Similar articles for PubMed (Select 23223430)

1.

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD.

Blood. 2013 Feb 14;121(7):1200-8. doi: 10.1182/blood-2012-09-453977. Epub 2012 Dec 6.

2.

Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.

Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C.

Blood. 2012 May 24;119(21):5021-9. doi: 10.1182/blood-2012-01-401885. Epub 2012 Apr 6.

3.

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.

Schmidt PJ, Racie T, Westerman M, Fitzgerald K, Butler JS, Fleming MD.

Am J Hematol. 2015 Apr;90(4):310-3. doi: 10.1002/ajh.23934.

4.

Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S.

J Clin Invest. 2013 Apr;123(4):1531-41. doi: 10.1172/JCI66969. Epub 2013 Mar 25.

5.

Hepcidin and Hfe in iron overload in beta-thalassemia.

Gardenghi S, Ramos P, Follenzi A, Rao N, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S.

Ann N Y Acad Sci. 2010 Aug;1202:221-5. doi: 10.1111/j.1749-6632.2010.05595.x. Review.

6.

Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.

De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A, Camaschella C.

Haematologica. 2006 Oct;91(10):1336-42.

7.

Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.

Finberg KE, Whittlesey RL, Andrews NC.

Blood. 2011 Apr 28;117(17):4590-9. doi: 10.1182/blood-2010-10-315507. Epub 2011 Feb 25.

8.

Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.

Lee P, Hsu MH, Welser-Alves J, Peng H.

Blood Cells Mol Dis. 2012 Mar 15;48(3):173-8. doi: 10.1016/j.bcmd.2011.12.005. Epub 2012 Jan 14.

9.

mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.

Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, Rechavi G.

Am J Hematol. 2006 Jul;81(7):479-83.

PMID:
16755567
10.

Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis.

Ramos P, Guy E, Chen N, Proenca CC, Gardenghi S, Casu C, Follenzi A, Van Rooijen N, Grady RW, de Sousa M, Rivella S.

Blood. 2011 Jan 27;117(4):1379-89. doi: 10.1182/blood-2010-09-307462. Epub 2010 Nov 8.

11.

Iron and hepcidin: a story of recycling and balance.

Camaschella C.

Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. doi: 10.1182/asheducation-2013.1.1.

12.

Exogenous iron increases hemoglobin in beta-thalassemic mice.

Ginzburg YZ, Rybicki AC, Suzuka SM, Hall CB, Breuer W, Cabantchik ZI, Bouhassira EE, Fabry ME, Nagel RL.

Exp Hematol. 2009 Feb;37(2):172-83. doi: 10.1016/j.exphem.2008.10.004. Epub 2008 Dec 6.

PMID:
19059700
13.

Hepcidin downregulation by repeated bleeding is not mediated by soluble hemojuvelin.

Krijt J, Fujikura Y, Sefc L, Vokurka M, Hlobenová T, Necas E.

Physiol Res. 2010;59(1):53-9. Epub 2009 Feb 27.

14.

Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis.

Muckenthaler M, Roy CN, Custodio AO, Miñana B, deGraaf J, Montross LK, Andrews NC, Hentze MW.

Nat Genet. 2003 May;34(1):102-7.

PMID:
12704390
15.

Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.

Haematologica. 2007 May;92(5):583-8.

16.

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S.

J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. Epub 2010 Nov 22.

17.

Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.

Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S.

Nat Genet. 2003 May;34(1):97-101.

PMID:
12704388
18.

Smad6 and Smad7 are co-regulated with hepcidin in mouse models of iron overload.

Vujić Spasić M, Sparla R, Mleczko-Sanecka K, Migas MC, Breitkopf-Heinlein K, Dooley S, Vaulont S, Fleming RE, Muckenthaler MU.

Biochim Biophys Acta. 2013 Jan;1832(1):76-84. doi: 10.1016/j.bbadis.2012.08.013. Epub 2012 Aug 31.

19.

Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.

Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ.

Br J Haematol. 2012 Jun;157(5):615-26. doi: 10.1111/j.1365-2141.2012.09104.x. Epub 2012 Mar 26.

PMID:
22449175
20.

Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S.

Blood. 2007 Jun 1;109(11):5027-35. Epub 2007 Feb 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk